Craig Behnke

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.